Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Enhanced Epilepsy Therapy with Genetic Analysis

12.03.2004


There are genetic differences between epilepsy patients that decide on whether medical treatment is successful or not. This is the result of a major study at the Vienna General Hospital. These new insights form the basis for an epilepsy therapy tailor-made for the needs of each individual patient. This study will be presented to the scientific community at the end of May at the largest European congress on epilepsy that will be taking place in Vienna this year.



As much as three percent of the population will contract epilepsy during the course of their lives. However, thanks to state-of-the-art medicines, two-thirds of all persons affected will be able to lead lives free of epileptic attacks, although one third respond less well to these drugs. These patients were the focus of a study with more than 630 test subjects carried out by the University Hospital of Neurology at the University Hospital of Neurology. This study was dedicated to unlocking the key to a phenomenon that has long since been known in this group of patients. Namely, why does the efficacy of drugs vary so strongly from one patient to the next? In the future, the results obtained from the study of Dr. Fritz Zimprich and his team will make it possible to make a dramatic improvement in the diagnosis of the efficacy of medical therapy.

We know that there are proteins that provide something akin to chemical detoxification and they are also to be found in the brain. These transport proteins ensure that potentially damaging substances are carried away from the cells. For a healthy organism, this protective mechanism makes a lot of sense. However, it can make it more difficult to treat diseased tissue with drugs because these proteins often transport medicines from the cells that are meant to cure them.


Dr. Zimprich, the head of the study, points out that "we have only known for a little while of the existence of these so-called multi-drug resistance proteins in the brain. We picked up on this by thinking that the known differences in drug efficacy from one epilepsy patient to another may be dependant upon how many of these proteins are active in the brain of each of these patients. In turn, the degree of activity may be impacted by minute variations in genes that code for these proteins."

There are at least two of these genes since every person has a set of two chromosomes. In this study, they compared the genetic sequence (symbolised by the letters A, C, G and T) of a very specific subsection of this pair of genes. The surprising finding was that five out of six of these epilepsy patients respond very poorly to drugs if the sequence is CGC on both subsections.

Dr. Zimprich provides further interpretation of the importance of these results: "Now, we are aware of the fact that this special section does not have a direct impact on the way the transport proteins functions. However, we think that this section may be something akin to an internal regulator that has a co-determining effect on how much of the protein is produced." In the future, we will be able to make reliable predictions on the efficacy of a medical therapy by analysing the pertinent gene sections of epilepsy patients. Beyond this, these insights will form the point of departure for future combined therapies where the transport proteins are switched off by additional therapeutic agents, thus augmenting the efficacy of traditional drugs.

Professor Christoph Baumgartner, the head of the Working Group for Clinical Epileptology, chairperson of the national organisational committee and Dr. Zimprich’s colleague, is especially proud that this study was concluded shortly before the 6th European Congress on Epileptology. "The European Congress of the International League against Epilepsy only takes place every two years and it will have its venue this year in Vienna from May 30 to June 3. This means that we will now be able to present this important research to the international scientific community in Vienna."

Till C. Jelitto | alfa
Further information:
http://www.epilepsyvienna2004.org

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

Im Focus: Newly proposed reference datasets improve weather satellite data quality

UMD, NOAA collaboration demonstrates suitability of in-orbit datasets for weather satellite calibration

"Traffic and weather, together on the hour!" blasts your local radio station, while your smartphone knows the weather halfway across the world. A network of...

Im Focus: Repairing defects in fiber-reinforced plastics more efficiently

Fiber-reinforced plastics (FRP) are frequently used in the aeronautic and automobile industry. However, the repair of workpieces made of these composite materials is often less profitable than exchanging the part. In order to increase the lifetime of FRP parts and to make them more eco-efficient, the Laser Zentrum Hannover e.V. (LZH) and the Apodius GmbH want to combine a new measuring device for fiber layer orientation with an innovative laser-based repair process.

Defects in FRP pieces may be production or operation-related. Whether or not repair is cost-effective depends on the geometry of the defective area, the tools...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Multiregional brain on a chip

16.01.2017 | Power and Electrical Engineering

New technology enables 5-D imaging in live animals, humans

16.01.2017 | Information Technology

Researchers develop environmentally friendly soy air filter

16.01.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>